



**3rd Dresden International Symposium
on Therapeutic Apheresis**
March 13 – 15, 2014
Lipidologische Fortbildung
March 14, 2014

Department of Medicine III
University Hospital Dresden
Fetscherstraße 74
01307 Dresden
Germany

Welcome

Dear colleagues,

This is already the third international symposium on therapeutic apheresis taking place in Dresden.

The aim is to organize a high level international conference on Lipoprotein apheresis and Immunoabsorption for autoimmune diseases. We hope that the lectures by prominent invited speakers will spark lively discussions and complete a comprehensive overview on the potential of apheresis as well as ways to reach therapeutic targets.

A special topic will be the presentation of new drugs for the treatment of hypercholesterolemia which have recently been developed or are already registered.

For this occasion, it is a pleasure to invite you to the beautiful city of Dresden, which, after decades of restauration shines anew these days. In fact, the University Hospital is just 15 minutes away from the very center of the old city. We hope to see you in Dresden.

With best regards,

Prof. Ulrich Julius

Prof. Bernd Hohenstein



Lipoprotein apheresis

Auditorium in the Dean's Building (House 40)

Thursday, March 13, 2014

- Chairpersons: Stefan R. Bornstein, Dresden; Markolf Hanefeld, Dresden
CME-Punkte: 7
- 13.00 - 13.40 **Lipoprotein(a) – what's new?**
Borge Nordestgaard, Copenhagen
- 13.40 - 14.05 **Screening activities for cardio-metabolic risk characterization**
Wolfgang Ramlow, Rostock
- 14.05 - 14.25 **Lipoprotein(a) as a risk factor in outpatients**
Sergey Tselmin, Dresden
- 14.25 - 14.40 **Effect of niacin on lipoprotein(a) level is dependent on apo(a) phenotypes**
Nadya Ertemeva, Moscow
- 14.40 - 15.10 **Efficacy of chronic lipoprotein apheresis in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease results of the prospective observational multicenter study Pro(a)LiFe**
Reinhard Klingel, Cologne
-
- Break**
-
- 15.30 - 15.50 **Lipoprotein apheresis in patients with refractory angina and raised lipoprotein(a)**
Tina Kahn, London
- 15.50 - 16.10 **Lipoprotein apheresis in patients with isolated elevated lipoprotein(a) – effects on the incidence of cardiovascular diseases**
Elisabeth Steinhagen-Thiessen, Berlin
- 16.10 - 16.30 **Effect of lipoprotein apheresis on the coronary blood flow in patients with high lipoprotein(a) levels**
Klaus Peter Mellwig, Bad Oynhausen
- 16.30 - 16.50 **Influence of lipoprotein apheresis on the lipoprotein(a) levels in the long run**
Elisa Groß, Dresden
- 16.50 - 17.30 **Do we need a lipoprotein apheresis specific for lipoprotein(a) – the Moscow experience**
Sergei Pokrovsky, Moscow; Marat Ezhov, Moscow
- 17.30 - 18.00 **Effects of lipoprotein apheresis on PCSK9 levels**
Ulrich Julius, Dresden
- 18.00 - 18.30 **PCSK9-inhibitors – a new class of lipid-lowering drugs**
Ionna Gouni-Bertholdt, Cologne

Friday, March 14, 2014

- Chairpersons: Claudia Stefanutti, Rome; Gilbert Thompson, London
CME-Punkte: 5
- 09.00 - 09.30 **Influence of lipoprotein apheresis on the kinetics of lipoproteins**
Klaus Parhofer, Munich
- 09.30 - 10.00 **Lipoprotein apheresis and cholesterol efflux**
Tiziana Sampietro, Pisa
- 10.00 - 10.30 **Effect of acute cholesterol lowering on lipoproteins**
Patrick Moriarty, Kansas
- 10.30 - 10.45 **Effect of lipoprotein apheresis on cytokines – new data**
Claudia Stefanutti, Rome
- 10.45 - 11.00 **New data on lipidomics in lipoprotein apheresis patients**
Jürgen Gräßler, Dresden
-
- Break**
-
- 11.15 - 11.35 **Dynamics of complement and rheological indicators after the therapy with rheohemapheresis**
Milan Blaha, Hradec Kralove
- 11.35 - 11.50 **Rheological effects of lipoprotein apheresis**
Beate Jäger, Mülheim-Ruhr
- 11.50 - 12.10 **First data from the German-Lipoprotein-Apheresis Registry (GLAR)**
Volker Schettler, Göttingen
- 12.10 - 12.30 **Actual situation of lipoprotein apheresis in Saxony in 2013**
Ulrike Emmrich, Dresden
- 12.30 - 12.50 **Detailed description of the cardiovascular situation in patients who have started an apheresis treatment**
Steffen Schampera, Dresden
- 12.50 - 13.20 **Long-term experience with lipoprotein apheresis**
Gennadi Konovalov, Moscow
- 19.30 **Gala Dinner (included)**
Swissôtel Dresden am Schloss, Schlossstraße 16,
01067 Dresden, Germany

Saturday, March 15, 2014

- Chairpersons: Patrick Moriarty, Kansas City; Wolfgang Ramlow, Rostock
CME-Punkte: 8
- 09.00 - 09.20 **Results of a novel therapeutic vaccine for lipoprotein(a) in mice**
Hironori Nakagami, Osaka
- 09.20 - 09.40 **Lp(a) pathology at the molecular level and introduction of novel Lp(a) lowering therapies beyond apheresis**
Gerd Schmitz, Regensburg
- 09.40 - 09.55 **Therapeutic apheresis in prevention of restenosis after coronary angioplasty (first experience)**
Valeri Tishko, Sankt Petersburg
- 09.55 - 10.10 **Lipoprotein apheresis in patients with peripheral occlusive arterial disease**
Kathrin Enke-Melzer, Berlin
- 10.10 - 10.30 **Efficacy, safety and tolerability of long-term lipoprotein apheresis in patients with LDL- and Lp(a)-hyperlipoproteinemia: experience from 35,000 treatments in a single center**
Franz Heigl, Kempten
- 10.30 - 10.50 **Lipoprotein apheresis in children – the Marburg experience**
Günter Klaus, Marburg
-
- Break**
-
- 11.00 - 11.20 **Managing homozygous FH from cradle to grave**
Gilbert Thompson, London
- 11.20 - 11.40 **Pregnancy in homozygous familiar hypercholesterolemia – when the things are going well**
Milan Blaha, Hradec Kralove
- 11.40 - 12.00 **Lomitapide in homozygous FH patients**
Maurizio Averna, Palermo
- 12.00 - 12.20 **Effect of lipids on cardiovascular autonomic regulation**
Tjalf Ziemssen, Dresden
- 12.20 - 12.40 **Nebenwirkungen der Lipoprotein-Apherese-Therapie**
Anja Ramlow, Rostock
- 12.40 - 13.00 **Pflegerische Aspekte der Apherese bei verschiedenen Behandlungsindikationen**
Ines Schulz-Merkel, Kempten
-
- Break**
-

Saturday, March 15, 2014

- Chairpersons: Bernd Hohenstein, Dresden; Ulrich Julius, Dresden
- 13.30 - 13.50 **Konsequenzen aus der steigenden Anzahl von Patienten in einem Apherese-Zentrum**
Kerstin Johné, Dresden
- 13.50 - 14.10 **HTG in an outpatient department – significance as an atherosclerotic risk factor**
Moritz Scholz, Dresden
- 14.10 - 14.40 **Severe hyperchylomicronemia and hypertriglyceridemia: why, when and how it is to be treated**
Claudia Stefanutti, Roma
- 14.40 - 15.00 **Effect of lipoprotein apheresis on FABP4 – long-term study**
Valeria Lamounier-Zepter, Dresden
- 15.00 - 15.20 **Comparison of two intravenous iron preparations in patients treated with lipoprotein apheresis**
Ulrike Schatz, Dresden
-
- Break**
-
- 15.40 - 16.00 **Beyond extracorporeal lipoprotein apheresis – impact on health-related quality of life in lipoproteinapheresis (LA) patients compared to patients with coronary heart disease (CHD) and to patients undergoing hemodialysis treatment (HD)**
Volker Schettler, Göttingen
- 16.00 - 16.20 **Psychische Situation von Apherese-Patienten im Vergleich zu Hämodialyse-Patienten**
Eva Stasiewsky, Dresden
- 16.20 - 16.30 **Concluding remarks**
Ulrich Julius, Dresden

H.E.L.P.
Just more than
LDL-Apheresis

B. BRAUN
SHARING EXPERTISE

Immunadsorption

House 19 Room 1.158

Friday, March 14, 2014

Chairpersons: Norbert Weiss, Dresden; Bernd Hohenstein, Dresden
CME-Punkte: 8

- 09.00 - 09.20 **Immunadsorption before and after renal transplantation**
Christian Hugo, Dresden
- 09.20 - 09.40 **Acquired Haemophilia: Conventional Treatment vs. Apheresis**
Heike Zeitler, Bonn
- 09.40 - 10.00 **Plasma exchange vs. immunadsorption in steroid refractory neuroinflammatory demyelinating diseases**
Johannes Mühlhausen, Göttingen
- 10.00 - 10.20 **Immunadsorption in autoimmune encephalitis**
Wolfgang Köhler, Wermsdorf
- 10.20 - 10.40 **Immunadsorption in multiple sclerosis**
Bernd Hohenstein, Dresden
- 10.40 - 11.00 **Immunadsorption in myasthenia gravis**
Kurt Derfler, Vienna
-
- Break**
- 11.20 - 11.40 **Antibodies against AT1-receptor in transplantation (diagnostic, treatment, clinical relevance)**
Dagmar Barz, Jena
- 11.40 - 12.00 **Therapeutic apheresis in pediatric patients with acute CNS inflammatory demyelinating disease**
Johannes Mühlhausen, Göttingen
- 12.00 - 12.20 **Therapie der Präeklampsie mittels sFlt-1-Apherese**
Holger Stepan, Leipzig
- 12.20 - 12.40 **Immunadsorption in thromboangitis obliterans**
Norbert Weiss, Dresden
- 12.40 - 13.00 **Immunadsorption in Thromboangitis obliterans – new data**
Peter Klein-Weigel, Berlin

Break

Friday, March 14, 2014

Chairpersons: Kurt Derfler, Vienna; Dagmar Barz, Jena

- 13.40 - 14.00 **Immunadsorption in SLE**
Kurt Derfler, Vienna
- 14.00 - 14.20 **Immunadsorption in children**
Theresa Kwon, Paris
- 14.20 - 14.40 **Immunadsorption in critical children in the hemato-oncology**
Volker Witt, Vienna
- 14.40 - 14.55 **Targeting suPAR in focal-segmental glomerulosclerosis by apheresis or immunadsorption – a therapeutic perspective?**
Christian Morath, Heidelberg
- 14.55 - 15.10 **Immunadsorption can improve cardiac function in transplant candidates with non-ischemic cardiomyopathy associated with diabetes mellitus**
Michael Dandel, Berlin
- 15.10 - 15.25 **Immunadsorption after heart transplantation**
Nick Banner, Harefield
- 15.25 - 15.45 **New generation of affinity sorbents for therapeutic apheresis**
Sergei Pokrovsky, Moscow
- 15.45 - 16.00 **The effect of plasma exchange and immunadsorption on the vaccination status**
Silke Rummler, Jena

Lipidologische Fortbildung

Auditorium in the Dean's Building (House 40)

Friday, March 14, 2014

Diese Veranstaltung wird im Rahmen der strukturierten curriculären Fortbildung Lipidologie DGFF (Lipidologie DGFF®) als Fortbildungsnachweis anerkannt.

Weitere Informationen hierzu sind erhältlich unter www.lipid-liga.de, Rubrik "Lipidologie DGFF".



Vorsitzende: Sabine Fischer, Dresden; Ulrich Julius, Dresden
CME-Punkte: 5

- 14.00 - 14.20 **25 Jahre Lipid-Liga**
Ulrich Klör, Gießen
- 14.20 - 14.45 **Die aktuelle Rolle der HDL im Rahmen der Atherogenese**
Klaus Parhofer, München
- 14.45 - 15.05 **Neue Leitlinien zur Cholesterinsenkung: ACC/AHA, ESC/EAS und IAS: wer hat recht?**
Eberhard Winder, Hamburg
- 15.05 - 15.30 **Diagnostische und therapeutische Optionen bei Patienten mit hohen Lipoprotein(a)-Spiegeln**
Elisabeth Steinhagen-Thiessen, Berlin
- 15.30 - 15.50 **Omega-3-Fettsäuren in der Lipidtherapie**
Ulrich Julius, Dresden
- 15.50 - 16.20 **Praktische Durchführung der medikamentösen lipidsenkenden Pharmakotherapie**
Sabine Fischer, Dresden
- 16.20 - 16.50 **Neue Entwicklungen in der lipidsenkenden Pharmakotherapie: Mipomersen, Lomitapide, PCSK9-Inhibitoren**
Heiner Bertholdt, Bielefeld

Scientific Program supported by:

- Fresenius Medical Care GmbH
- Kaneka Pharma Europe N.V.
- B. Braun Avitum AG
- Miltenyi Biotec GmbH
- DIAMED Medizintechnik GmbH
- STADapharm GmbH
- Sanofi-Aventis Deutschland GmbH
- Breu GmbH
- medicap clinic GmbH
- AMGEN GmbH
- Aegerion Pharmaceuticals GmbH
- Novartis Pharma GmbH
- MSD Sharp & Dohme GmbH (1500 EUR)
- PakuMed GmbH
- Abbott Arzneimittel Deutschland (800 EUR)
- PENTRACOR GmbH

Gemäß FSA-Kodex – § 20 Abs. 5 sind die im FSA vereinten Firmen verpflichtet, den Umfang des Sponsorings für Veranstaltungen offenzulegen. Jeweils für Werbemöglichkeiten und Standkosten.

Die Offenlegung erfolgt auch im Internet www.carus-management.de und während der Veranstaltung.

How to find us



Overview University Hospital Dresden

University Hospital Dresden
Department of Medicine III
Fetscherstraße 74
01307 Dresden

International Travel

Dresden International airport is approximately 30 minutes from the clinical center and served by regional railway. International trains arrive both at Dresden main station and at Dresden Neustadt with convenient connections to tramway lines.

Public Transport

The University Hospital is served by tramway lines 6 and 12 (Stop: Augsburger Straße/ Universitätsklinikum) as well as bus lines 64 and 62 (Stop: Universitätsklinikum).

Car

For fee parking is available at the Fiedlerstraße main entrance parking deck with room for 500 cars.

Registration

Please register by sending or faxing the attached form to the Carl Gustav Carus Management GmbH.
www.carus-management.de

You can also register via E-mail:
CGCManagementGmbH@uniklinikum-dresden.de

Or write an E-mail to:
ulrich.julius@uniklinikum-dresden.de

The registration fee for participants is 80 EUR by March 01, 2014 – thereafter the registration fee will be 100 EUR (physicians / scientists in training 40 EUR, students (with ID) 20 EUR).

The Gala Dinner will be included.

CME points have been affirmed by the Sächsische Landesärztekammer.

Updated information about the symposium including the scientific program will be provided on the following website:

www.uniklinikum-dresden.de/mk3

Bank:

Deutsche Kreditbank AG
Account No.: 11 248 333
Bank code: 120 300 00

IBAN: DE 71 1203 0000 0011 248 333
BIC: BYLADEM 1001

Registration form:

Please send or fax this filled form to the conference agency until February 28, 2014!

Carl Gustav Carus Management GmbH Phone: +49 351-458-4469
Fetscherstr. 74 Fax: +49 351-458-6323
01307 Dresden E-Mail: CGCManagementGmbH@uniklinikum-dresden.de

- 3rd Dresden International Symposium on Therapeutic Apheresis
 Lipidologische Fortbildung
(Teilnahme kostenfrei / DGFF Lipid-Liga e.V.)

Surname	First Name
Title	
Address	
E-Mail	

Registration fee (Financial Management: CGC Management GmbH)

- 80 € (before March 01, 2014) 100 €
 40 € Physician/Scientist in Training 20 € Student (with ID)

Participation in Gala Dinner March 14, 2014 Yes No

I will pay by bank transfer.

Bank: Deutsche Kreditbank AG

Für die vertragliche und finanzielle Abwicklung dieser Veranstaltung zeichnet die Carl Gustav Carus Management GmbH verantwortlich.

IBAN: DE 71 1203 0000 0011 248 333 · BIC: BYLADEM 1001

I will pay by credit card.

I authorize the charge of the registration fee.

VISA MASTERCARD

Card No.: _____

Expiry date: ____/____/____ Cardholder: _____

Date: _____ Signature: _____



Antwort

Carl Gustav Carus Management GmbH
Fetscherstraße 74
01307 Dresden
Germany